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CASE REPORT Open Access
Radiation recall after capecitabine in a
patient with recurrent nasopharyngeal
carcinoma: a case report
Victor Lee1,2*, Ka-On Lam1, Dora Kwong1 and To-Wai Leung1
Abstract
Background: Capecitabine has been commonly used in recurrent or metastatic nasopharyngeal carcinoma.
However, radiation recall after capecitabine for nasopharyngeal carcinoma has not been reported.
Case presentation: We report the case of a 64-year-old Chinese woman with locoregionally advanced
nasopharyngeal carcinoma previously treated with induction chemotherapy followed by concurrent chemoradiation
6 years ago. She developed cervical, mediastinal, and abdominal nodal relapses 14 months later. She then received
capecitabine with initial excellent tumor response for 1 year but disease recurrence was noticed at the peripancreatic
nodal region, which was successfully treated with concurrent chemoradiation with capecitabine. Unfortunately, she
developed progressive erythema of the face and neck region at exactly the previous irradiation site for her initial
nasopharyngeal carcinoma, 2 months after taking capecitabine. She initially ignored it, but it became more confluent
and serious. Eventually, a facial skin biopsy was performed showing nonspecific chronic inflammation only. The
diagnosis was most likely radiation recall phenomenon since capecitabine was the only drug she received before
development of this dermatological manifestation on her previously irradiated face and neck. Treatment was
conservative and supportive albeit with no significant clinical improvement.
Conclusions: Radiation oncologists should be aware of this potential risk of capecitabine, especially when it is
administered for a long period of time.
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Background
Radiation recall is a rare and acute dermatological con-
dition typically occurring at the site of previous radiation
therapy, after administration of a certain type of oral or
intravenous medication particularly chemotherapeutic
agent(s) or, less likely, targeted therapies [1–4]. Skin is
the most common site of manifestation with incidence
between 6 and 11 % according to previous literature [5].
The time lapse between previous radiation therapy and
the onset of radiation recall after use of the causative
drug varies, ranging from days to months or even many
years after the last radiation therapy [2, 4–6]. It has also
been recently postulated that the severity of radiation re-
call is associated with the dose of the medication. Treat-
ment would be most likely conservative with modest
improvement after use of topical or systemic glucocorti-
coids, but the condition may persist even if the causative
drug is withdrawn, especially when there is irreversible
damage to the dermis.
Capecitabine, a prodrug of 5-fluorouracil, has been
commonly employed in the treatment of breast cancer,
upper and lower gastrointestinal cancer, and pancreatic
cancers and thus all patients who were previously re-
ported to suffer from radiation recall after capecitabine
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had their primary tumors in these tracts [7–11]. Capecit-
abine, in fact, is also active for nasopharyngeal carcin-
oma (NPC), an endemic disease in Southern China
including Hong Kong, as shown in previous phase II and
III studies [12–16]. Some case reports were published
on radiation recall in patients previously treated for their
head and neck cancers [17–19]. To the best of our
knowledge, no report has been published on radiation
recall after use of capecitabine for NPC. We here report
the case of a patient who suffered from radiation recall
phenomenon at her faciocervical region previously irra-
diated for her NPC, after taking capecitabine for her
more recently developed cervical, mediastinal, and ab-
dominal nodal relapse 1 year after radical chemoradia-
tion for her NPC.
Case presentation
A 64-year-old Chinese woman was diagnosed to have
stage IVB T1N3bM0 undifferentiated type of nasopha-
ryngeal carcinoma (NPC) 6 years ago. Pretreatment
plasma Epstein-Barr virus (EBV) deoxyribonucleic acid
(DNA) was 827 copies/mL. She received induction
chemotherapy consisting of one cycle of cisplatin and 5-
fluorouracil and two more cycles of carboplatin (area-
under-the-curve value 5) plus 5-fluorouracil in view of
her deteriorating renal function, followed by radical che-
moradiation using carboplatin concurrent with intensity-
modulated radiation therapy (IMRT) with 70 Gy in 33
fractions to the gross primary tumor and neck nodes
and 66 Gy in 33 fractions to the high-risk primary and
neck nodal regions, all over 6.5 weeks delivered by
Simultaneous Accelerated Radiation Therapy (SMART)
technique completed 5 months later. Posttreatment
plasma Epstein-Barr virus deoxyribonucleic acid (EBV
DNA) became undetectable at 8 weeks after IMRT. Un-
fortunately, her disease relapsed 14 months later with
lymph node metastases to the left supraclavicular fossa
and the right superior mediastinal region, together with
a distant lymph node metastasis at the peripancreatic re-
gion revealed by [18 F]fluorodeoxyglucose positron
emission tomography with integrated computed tomog-
raphy (PET-CT) (Fig. 1). Plasma EBV DNA rose to 338
copies/mL. In view of distant metastasis, she started
capecitabine at 1000 mg/m2 twice daily from day 1 to
14 and every 3 weeks afterward and titrated up to
1250 mg/m2 twice daily from day to 1 to 14 every 3
weeks from cycle 3 onward with a significant drop of
plasma EBV DNA to 0 copies/mL after taking cape-
citabine for 7 months. She continued capecitabine up
to 1 year until further disease progression with increasing
in size of the peripancreatic lymph node metastasis with
plasma EBV DNA elevation to 64 copies/mL. In view of
the solitary peripancreatic nodal disease, she received con-
formal radiotherapy (50 Gy in 25 fractions over 5 weeks)
to the peripancreatic lymph node concurrent with capecit-
abine 825 mg/m2 twice daily and 5 days a week on
radiotherapy days only. Plasma EBV DNA dropped to
0 copies/mL and her PET-CT scan 9 months later
confirmed complete metabolic response of the peripan-
creatic lymph node. Capecitabine was then stopped after
the complete response demonstrated in this latest PET-
CT scan. Unfortunately, she noticed that her face grad-
ually developed progressive erythema and increasing
warmth with relative sparing of the nostrils and perinasal
region 2 months after taking capecitabine. It was initially
ignored by our patient until the skin erythema became
more confluent and prominent at the irradiation site of
the previous IMRT for her initial NPC (Fig. 2a-c). It did
not subside with capecitabine cessation as well as applica-
tion of emollients, topical and oral steroids, and even anti-
biotics. A skin biopsy showed nonspecific inflammation
only. As the dermatological manifestation was confined to
her face and neck only and she had not received any other
oral or topical medication except capecitabine, radiation
recall was the most likely underlying diagnosis to account
for her current skin condition. She received a course of
laser therapy prescribed by a private dermatologist but the
skin condition prevailed (Fig. 2d). Unfortunately, her facial
skin condition has been persistent for more than 4 years
though no further evidence of NPC recurrence has been
noted so far.
Discussion
Capecitabine is rarely used as part of systemic chemo-
therapy in head and neck squamous cell carcinoma but
it is more commonly used in breast, esophageal, gastric,
colorectal, and pancreatic cancers [7–11]. On the other
hand, capecitabine is one of the most commonly
prescribed regimes for recurrent and metastatic NPC, a
separate disease entity from head and neck squamous
cell carcinoma based on its different etiology and geo-
graphical epidemiology, since the response rate ranges
from 23.5 % as monotherapy to 62.5 % when used in
combination with cisplatin [12–15]. More recently, cape-
citabine has also been found efficacious as induction
Fig. 1 Positron emission tomography with integrated computed
tomography image showing the hypermetabolic peripancreatic
nodal relapse (red arrow)
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chemotherapy followed by concurrent chemoradiation in
a phase III randomized controlled trial conducted in
Hong Kong [16]. Radiation recall related to prior use of
capecitabine has been reported in patients with breast
and pancreatic cancers [20–22]. However, it has not
been reported so far in head and neck cancers, including
NPC. The exact pathophysiology for radiation recall
phenomenon remains to be deciphered. Vascular dam-
age, epithelial stem cell sensitivity or hypersensitivity to
chemotherapeutic agents have been postulated as the
underlying mechanisms [5, 23]. More recently, thymi-
dine phosphorylase, a potent angiogenic factor was
shown to be associated with the development of radi-
ation recall after capecitabine use [22, 24]. Sawada et al.
revealed that external radiotherapy induces thymidine
phosphorylase and it enhanced the efficacy of capecita-
bine in human cancer xenografts [25]. Thymidine
phosphorylase produces 2-deoxy-D-ribose-1-phosphate
during thymidine catabolism, which in turn generates
oxygen radical species during the early stages of protein
glycation. It was suggested that thymidine led to oxida-
tive stress in thymidine phosphorylase-overexpressing
cancer cells, leading to production of stress-induced an-
giogenic factors, vascular endothelial growth factor, and
interleukin-8 and induced matrix metalloproteinase 1,
accounting for thymidine phosphorylase-induced angio-
genesis [22, 25]. Upregulation of thymidine phosphoryl-
ase by previous external radiotherapy gave rise to
development of angiogenesis in the previously irradiated
region, leading to hypervascularity and erythema. In fact,
the well-recognized palmar-plantar erythrodysethesia
(hand-foot syndrome) as a common side effect of cape-
citabine, may be due to this hypervascularity sequela.
Since our patient had received capecitabine continuously
for more than 1 year, the accumulative dose of capecita-
bine might predispose to the development and persist-
ence of her radiation recall. Treatment for radiation
recall is most largely conservative with close surveil-
lance. The subsequent irreversible damage of the under-
lying dermis brought about by prolonged exposure to
capecitabine may explain her poor response to symp-
tomatic treatment. Medication like moisturizers, antihis-
tamines or emollients may alleviate symptoms of
desquamation, itchiness or warmth. Topical or systemic
glucocorticoids may help reduce the inflammatory re-
sponse but they are usually not curative. Laser therapy,
as our patient received as per self-intention, was not
proven effective in alleviating the skin condition. Response
rates to these symptomatic treatment have been poorly
understood as they heavily depend on the pharmacokinet-
ics of the causative agent, duration of use of the causative
agent, and whether irreversible skin damage has occurred
or not [2, 5]. Usually the recall reaction may resolve more
rapidly after discontinuation of intravenous agents rather
than oral treatment. Some reactions to intravenous agents
may improve within hours. However, it may takes weeks,
months or even longer for the recall reaction to resolve,
especially if the causative agent is an oral medication [2].
Conclusions
In summary, this is the first case of radiation recall re-
lated to capecitabine in a patient with recurrent NPC.
Fig. 2 Radiation recall phenomenon after capecitabine for our patient who suffered from recurrent nasopharyngeal carcinoma. a Forehead and
face. b Right face and ear. c Left face and ear. d Persistent appearance after laser therapy
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Radiation oncologists should be vigilant of this potential
complication associated with capecitabine especially
when it is used for a long period of time. Treatment is
mainly supportive though significant clinical improve-
ment is not expected.
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